Bayer launches Aleve PM; Canada green-lights BMS' Yervoy;

> Bayer has launched Aleve PM, a pain reliever and sleep-aid combo. Release

> Health Canada has approved Bristol-Myers Squibb's ($BMY) Yervoy for first-line treatment of adults with metastatic melanoma. Release

> Novo Nordisk's ($NVO) new long-acting insulin, Tresiba, is effective and safe for long-term use in children and young adults with Type 1 diabetes, a new study shows. Report

> Danish drugmaker Lundbeck has launched antidepressant Brintellix in its home market, its first EU rollout. Report

> AbbVie ($ABBV) and Biogen Idec's ($BIIB) experimental multiple sclerosis med Zinbryta topped Biogen's Avonex on some measures in a Phase III trial. More

> Almost 90 lives could be saved every year if almost all teenage girls were given HPV vaccinations, experts say. More

And Finally... The U.S. government says Bayer makes unproven statements about the health benefits of a popular probiotic. More

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Disorder: The Rare Disease Film Festival is back and bigger than ever, set for a West Coast debut with 50 films this fall.